Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 4 SUPPL., 2010, Pages

  Duray, Gabor Z ^a   Schmitt, Jörn ^a   Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

antiarrhythmic drugs; atrial fibrillation; dronedarone; hospitalization; mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; PLACEBO; AMIODARONE; CREATININE;

ARTICLE; BRADYCARDIA; CONGESTIVE HEART FAILURE; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LUNG TOXICITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINUS RHYTHM; THYROID TOXICITY; TREATMENT DURATION; VOMITING; ANTIARRHYTHMIC ACTIVITY; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; LUNG DISEASE; NONHUMAN; SIDE EFFECT; TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 78649834234     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410368530     Document Type: Article

References (23)

1. Go AS, Hylek EM, Philips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 ; 285 (18). 2370-2375.
2. Greenlee RT, Vidaillet H. Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol. 2005 ; 20 (1). 7-14.
3. Feinberg WM, Blackshear JL, Laupacis A., Kronmal R., Hart RG Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995 ; 155 (5). 469-473.
4. Heist EK, Ruskin JN Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis. 2006 ; 48 (4). 256-269.
5. Dulli DA, Stanko H., Levine RL Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003 ; 22 (2). 118-123.
6. Wang TJ, Massaro JM, Levy D., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003 ; 290 (8). 1049-1056.
7. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000 ; 356 (9244). 1789-1794.
8. Van Gelder IC, Hagens VE, Bosker HA, et al, for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002 ; 347 (23). 1834-1840.
9. Wyse DG, Waldo AL, DiMarco JP, et al, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347 (23). 1825-1833.
10. Carlsson J., Miketic S., Windeler J., et al, STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003 ; 41 (10). 1690-1696.
11. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 ; 358 (25). 2667-2677.
12. Vorperian VR, Havighurst TC, Miller S., January CT Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997 ; 30 (3). 791-798.
13. Ehrlich JR, Biliczki P., Hohnloser SH, Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol. 2008 ; 51 (8). 787-792.
14. Hynes BJ, Luck JC, Wolbrette DL, Khan M., Naccarelli GV A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiol. 2005 ; 1 (2). 135-144.
15. Sablayrolles S., Le Grand B. Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent. Curr Opin Investig Drugs. 2006 ; 7 (9). 842-849.
16. Wegener FT, Ehrlich JR, Hohnloser SH Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol. 2006 ; 17 (suppl 2). S17 - S20.
17. Touboul P., Brugada J., Capucci A., Crijns HJ, Edvardsson N., Hohnloser SH Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003 ; 24 (16). 1481-1487.
18. Singh BN, Connolly SJ, Crijns HJ, et al, EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 ; 357 (10). 987-999.
19. Kober L., Torp-Pedersen C., McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 ; 358 (25). 2678-2687.
20. Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W., Torp-Petersen C. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008 ; 19 (1). 69-73.
21. Hohnloser SH, Crijns HJ, van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 ; 360 (7). 668-678.
22. Connolly SJ, Crijns HJ, Torp-Pedersen C., et al, for the ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009 ; 120 (13). 1174-1180.
23. Solomon SC, Dobson J., Pocock S., et al, for the CHARM Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007 ; 116 (13). 1482-1487.